Tirzepatide storage and stability: what is published versus what is assumed — does this still hold?

The question in the title: Tirzepatide storage and stability: what is published versus what is assumed — does this still hold? I will give what I have already checked below so nobody repeats it.

Asking about Tirzepatide storage and stability directly, because I have read four threads on it and each answered a slightly different question.

The version I want answered is the narrow one: given the method stated below, is the result within what anyone else has seen? I am not asking what it means yet.

Method, numbers and the two assumptions I am aware of making are below. If the assumptions are wrong that is more useful to me than agreement.

Thank you for taking the time. That was more work than a reply usually is.

Research-use-only tirzepatide is not approved for human use and is not made to pharmaceutical standards. Anyone discussing it here is describing what they did, not recommending it.

I would rather be precise about what I do not know than vague about what I do.

On purity: the trailing-edge features people report on tirzepatide chromatograms are frequently deamidation products, which elute close to the main peak and are easy to integrate into it. That is a method question rather than a quality question.

Coming back to post #3, because the follow-up matters more than the original answer.

On storage: published stability data covers the licensed formulation at its licensed concentration. A research preparation reconstituted at home in a different diluent at a different concentration is outside every one of those conditions.

Post #3 is right about the mechanism and I think understates the practical bit.

Heart rate rises modestly across this class, tirzepatide included. It is consistent, small, and worth knowing about rather than worth alarm — and it is one of the reasons the trials monitored it explicitly.

One of those cases where knowing the mechanism does not help the decision.

The five maintenance doses in the tirzepatide programme give a genuine dose-response curve, which is unusual. Most trials in this space compare one or two doses against placebo and cannot say anything about the shape of the relationship.

I would treat that as a working assumption and revisit it.

SURMOUNT-4's randomised withdrawal design is the strongest available evidence about what happens on stopping. It says nothing about a lower maintenance dose, because the comparison was continue versus placebo rather than continue versus less.

On balance I think that is right, and I would not bet much on it.

Storage and stability: published data on licensed tirzepatide formulations exists and is worth reading directly rather than through summarised claims. Reconstituted preparations in different diluents have not been studied and extrapolation from the licensed formulation is the best you can do.

Tirzepatide's half-life of roughly five days means steady state is approached in about three weeks rather than four. That is a real difference from semaglutide and it is small enough that the weekly schedule is unaffected.

SURPASS-2 compared tirzepatide with semaglutide 1.0 mg, the licensed diabetes dose at that time. It did not compare with semaglutide 2.4 mg, the highest approved dose. That is the central and legitimate criticism of the head-to-head evidence and it is worth remembering when people quote the trial.

The conclusion is tentative; the arithmetic underneath it is not.

Half-life difference: tirzepatide is about 5 days versus semaglutide's week-long. Practically, that means steady state is reached slightly faster and the post-dose swing is slightly larger. Most people do not report noticing the difference in practical terms.

Where I part company with post #10, and it is a narrow parting.

Content versus purity applies here as everywhere: a lyophilised vial can be highly pure and contain less peptide than the label states, because the balance of the mass is water, counter-ion and excipient.

Nothing above should be read as advice about what anyone else should do.